Clinical Biospecimen Collection

NCT07543159 | Recruiting

• 1 other identifier: WCG Protocol #20253750
• Study Type: observational
• Target: 900,000
• Locations: 1 country
• Sites: 1

Brief Summary

New York Cancer and Blood Specialists(NYCBS) is dedicated to provide world-class, patient-centered, affordable care to patients with cancer and blood disorders in their own communities, close to family and friends. Our vision is a world free of cancer and blood disorders by contributing to the search for cures by offering cutting-edge clinical trials and personalized, state-of-the-art treatments that save and prolong lives. In support of these objectives NYCBS has created a centralized oncology biorepository in tandem with a longitudinal study to support translational research. This study establishes a biological sample bank and associated data reservoir from thousands of cancer patients, high risk populations, and survivors. This means it collects and stores samples and information over time, throughout the course of a patient's cancer treatment. Researchers will then use these samples and information to better understand how cancer affects the body over time in order to formulate new treatments. The information and samples provided will allow the testing of new therapies and aid in the development of new medical treatments.

Conditions

Cancer Risk

Keywords

New York Cancer; Oncology; Cancer; Clinical Trial; Biobank; Umbrella

Outcome Measures

Primary Outcomes (1)

• Development of Assays, or Novel Diagnostic's and Treatments to Improve the Quality/Quantity of life for diseased individuals.

  Expedite development of diagnostic assays and/or novel treatments to improve the quality and/or quantity of life for diseased individuals. Samples may also be utilized in the development of commercial diagnostic reagents." Reagents such as RNA, DNA, and proteins may be involved. Use of this genetic information may aid in the development of novel diagnostics and therapies for patients with certain diseases.

  10 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Subjects diagnosed with or suspected of having cancerous disease, or from healthy, normal donors with the goal of aiding in biomarker research, early detection of disease, and development of new devices or therapies.

You may qualify if:

• Subjects must be at least 18 years of age
• Subjects must be deemed competent by a qualified clinical study researcher to provide legally documented informed consent
• Subjects may or may not have active disease at the time of enrollment
• Biospecimens collected under this protocol may be obtained from subjects with benign conditions, subjects who have been diagnosed with or suspected of having oncological diseases, infectious diseases, auto-immune diseases, endocrine disorders, as well as subjects from healthy normal donors.

Sponsors & Collaborators

• North Shore Hematology Oncology Associates P.C dba New York Cancer and Blood Specialists: lead

Study Sites (1)

NYCBS

Shirley, New York, 11967, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

* Cells and tissue(s) from procedures such as biopsies, fine needle aspiration (a minimally invasive medical procedure that involves inserting a thin needle into a suspicious area of the body to collect cells or tissue), core biopsies (a minimally invasive procedure that uses a hollow needle to remove a sample of tissue), or any other standard collection procedure * Whole blood, blood slides (a thin layer of blood placed on a glass microscope slide for diagnostic analysis), plasma (the liquid portion of blood, which carries nutrients and proteins throughout the body), serum (the fluid component of blood after it has clotted and the blood cells and clotting proteins have been removed), saliva, mucus, urine, stool, punch biopsies, hair, nail clippings, and other minimal risk biospecimens

MeSH Terms

Conditions

Neoplasms

Central Study Contacts

Andrew Lee, MHA

CONTACT

16313935767; Biobanking@nycancer.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator, Chief Medical Officer

Study Record Dates

• First Submitted: April 15, 2026
• First Posted: April 21, 2026
• Study Start: December 23, 2025
• Primary Completion (Estimated): October 6, 2035
• Study Completion (Estimated): October 6, 2035
• Last Updated: April 24, 2026

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)